{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T05:17:06Z","timestamp":1777612626460,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,5,1]],"date-time":"2016-05-01T00:00:00Z","timestamp":1462060800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":1461,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["kidney-international.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1016\/j.kint.2016.01.011","type":"journal-article","created":{"date-parts":[[2016,3,11]],"date-time":"2016-03-11T00:00:59Z","timestamp":1457654459000},"page":"988-994","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant"],"prefix":"10.1016","volume":"89","author":[{"given":"Fabrizio","family":"Fabrizi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piergiorgio","family":"Messa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 109","key":"10.1016\/j.kint.2016.01.011_bib1","first-page":"S1","article-title":"KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease","volume":"73","year":"2008","journal-title":"Kidney Int"},{"key":"10.1016\/j.kint.2016.01.011_bib2","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1365-2893.2012.01633.x","article-title":"Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality?","volume":"19","author":"Fabrizi","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.kint.2016.01.011_bib3","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/jvh.12148","article-title":"Meta-analysis of observational studies: hepatitis C and survival after renal transplant","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.kint.2016.01.011_bib4","doi-asserted-by":"crossref","first-page":"3801","DOI":"10.1007\/s10620-015-3801-y","article-title":"Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis","volume":"60","author":"Fabrizi","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.kint.2016.01.011_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1053\/j.gastro.2015.09.007","article-title":"Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies","volume":"150","author":"Petta","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.kint.2016.01.011_bib6","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/hep.26892","article-title":"Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients","volume":"59","author":"Hsu","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2016.01.011_bib7","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1159\/000355615","article-title":"Hepatitis C infection is very rarely treated among haemodialysis patients","volume":"38","author":"Goodkin","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.kint.2016.01.011_bib8","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1111\/jvh.12276","article-title":"Antiviral therapy (pegylated interferon and ribavirin) of hepatitis C in dialysis patients: meta-analysis of clinical studies","volume":"21","author":"Fabrizi","year":"2014","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.kint.2016.01.011_bib9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.7326\/0003-4819-159-11-201312030-00005","article-title":"Pegylated interferon-alpha2a with or without low-dose ribavirin for treatment-na\u00efve patients with hepatitis C virus genotype 1 receiving haemodialysis: a randomized trial","volume":"159","author":"Liu","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.kint.2016.01.011_bib10","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1136\/gutjnl-2014-307080","article-title":"Pegylated interferon alpha-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial","volume":"64","author":"Liu","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.kint.2016.01.011_bib11","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jhep.2006.12.016","article-title":"The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant","volume":"46","author":"Rendina","year":"2007","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.kint.2016.01.011_bib12","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C Guidance: AASLD-IDSA Recommendations for Testing, Managing, and Treating Adults Infected With Hepatitis C Virus. AASLD\/IDSA HCV Guidance Panel","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2016.01.011_bib13","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jvh.12422","article-title":"Interferon-free, direct acting antiviral therapy for chronic hepatitis C","volume":"22","author":"Gutierrez","year":"2015","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.kint.2016.01.011_bib14","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.clinre.2014.12.007","article-title":"Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen\u2014the ANRS CO20-CUPIC study","volume":"39","author":"Bailly","year":"2015","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.kint.2016.01.011_bib15","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.jcv.2012.10.009","article-title":"Antiviral triple therapy with telaprevir in haemodialysis patients: is it feasible","volume":"56","author":"Dumortier","year":"2013","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.kint.2016.01.011_bib16","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1111\/apt.12748","article-title":"Telaprevir triple therapy in chronic hepatitis C genotype 1 patients receiving haemodialysis","volume":"39","author":"Wiegand","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.kint.2016.01.011_bib17","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.17554\/j.issn.2224-3992.2014.03.470","article-title":"Response guided treatment with telaprevir or boceprevir in end stage renal disease patients with hepatitis C genotype 1","volume":"3","author":"Patel","year":"2014","journal-title":"J\u00a0Gastroenterol Hepatol Res"},{"key":"10.1016\/j.kint.2016.01.011_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.dld.2013.08.133","article-title":"Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation","volume":"46","author":"Knapstein","year":"2014","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.kint.2016.01.011_bib19","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jcv.2014.05.008","article-title":"Telaprevir pharmacokinetics in a hepatitis C virus infected patient on haemodialysis","volume":"60","author":"de Kanter","year":"2014","journal-title":"J\u00a0Clin Virol"},{"key":"10.1016\/j.kint.2016.01.011_bib20","first-page":"1","article-title":"Evaluation of telaprevir-containing triple therapy in the treatment of chronic hepatitis C in haemodialysis patients","volume":"2","author":"Kaya","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.kint.2016.01.011_bib21","doi-asserted-by":"crossref","DOI":"10.1179\/2295333715Y.0000000046","article-title":"A\u00a0case report: antiviral triple therapy with telaprevir in a haemodialysed HCV patient in Turkey","author":"Akhan","year":"2015","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.kint.2016.01.011_bib22","article-title":"Boceprevir-based triple antiviral therapy for chronic hepatitis C virus infection in kidney-transplant candidates","author":"Mehawej","year":"2015","journal-title":"J\u00a0Transplant"},{"key":"10.1016\/j.kint.2016.01.011_bib23","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","article-title":"Sofosbuvir and velpatasvir for HCV genotype 1,2,4,5, and 6 infection","volume":"373","author":"Feld","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.01.011_bib24","doi-asserted-by":"crossref","first-page":"2608","DOI":"10.1056\/NEJMoa1512612","article-title":"Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection","volume":"373","author":"Foster","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.01.011_bib25","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.kint.2016.01.011_bib26","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1053\/j.gastro.2010.07.009","article-title":"A\u00a0sustained virologic response is durable in patients with chronic hepatitis C treated with peg-interferon alfa2a and ribavirin","volume":"139","author":"Swain","year":"2010","journal-title":"Gastroenterology"},{"issue":"10003","key":"10.1016\/j.kint.2016.01.011_bib27","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","article-title":"Grazoprevir plus elbasvir in treatment-na\u00efve and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease (the C-SURFER study): a combination phase 3 study","volume":"386","author":"Roth","year":"2015","journal-title":"Lancet"},{"issue":"suppl 1","key":"10.1016\/j.kint.2016.01.011_bib28","first-page":"A1039","article-title":"RUBY-I: ombitasvir\/paritaprevir\/ritonavir+dasabuvir+\/- ribavirin in non-cirrhotic HCV genotype 1-infected patients with severe renal impairment or end-stage renal disease","volume":"62","author":"Pockros","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.kint.2016.01.011_bib29","article-title":"Dosing recommendations for concomitant medications during 3D anti-HCV therapy","author":"Badri","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.kint.2016.01.011_bib30","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3109\/23744235.2015.1078908","article-title":"Use of sofosbuvir-based direct acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency","volume":"47","author":"Hundemer","year":"2015","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.kint.2016.01.011_bib31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jhep.2015.06.004","article-title":"Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of hepatitis C in patients with end stage renal disease","volume":"63","author":"Bhamidimarri","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.kint.2016.01.011_bib32","article-title":"Sofosbuvir and simeprevir in hepatitis C genotype 1-infected patients with end-stage renal disease on haemodialysis or GFR< 30 mL\/min","author":"Nazario","year":"2015","journal-title":"Liver Int"},{"key":"10.1016\/j.kint.2016.01.011_bib33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/tid.12348","article-title":"Sofosbuvir and simeprevir combination therapy in the setting of liver transplantation and haemodialysis","volume":"17","author":"Perumpail","year":"2015","journal-title":"Transpl Infect Dis"},{"key":"10.1016\/j.kint.2016.01.011_bib34","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1111\/tri.12622","article-title":"Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: viral eradication and removal from the liver transplant waiting list","volume":"28","author":"Bonacci","year":"2015","journal-title":"Transpl Int"},{"key":"10.1016\/j.kint.2016.01.011_bib35","doi-asserted-by":"crossref","first-page":"S267","DOI":"10.1016\/S0168-8278(15)30162-8","article-title":"Safety and efficacy of sofosbuvir-containing regimens in HCV infected patients with reduced renal function: real-world experience from HCV-TARGET","volume":"62","author":"Saxena","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.kint.2016.01.011_bib36","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1053\/j.ajkd.2012.08.040","article-title":"Hepatitis C virus infection, mixed cryoglobulinemia, and kidney disease","volume":"61","author":"Fabrizi","year":"2013","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.kint.2016.01.011_bib37","article-title":"Treatment of hepatitis C virus-associated mixed cryoglobulinemia with sofosbuvir-based direct-acting antiviral agents","author":"Sise","year":"2015","journal-title":"Hepatology"}],"container-title":["Kidney International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253816002921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0085253816002921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:48:55Z","timestamp":1758761335000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0085253816002921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":37,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["S0085253816002921"],"URL":"https:\/\/doi.org\/10.1016\/j.kint.2016.01.011","relation":{},"ISSN":["0085-2538"],"issn-type":[{"value":"0085-2538","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New treatment for hepatitis C in chronic kidney disease, dialysis, and transplant","name":"articletitle","label":"Article Title"},{"value":"Kidney International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.kint.2016.01.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}